Updating results

What is the prognostic value of different risk stratification methods for people with locally advanced prostate cancer?

Recommendation ID NG131/7 Question What is the prognostic value of different risk stratification methods for people with locally advanced

Research recommendation Published October 2019

What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

Recommendation ID NG131/3 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate

Research recommendation Published October 2019

What methods and techniques help secondary schools and providers to effectively engage with parents and carers as part of a whole-school approach to promote and support alcohol education?

Recommendation ID NG135/6 Question What methods and techniques help secondary schools and providers to effectively engage with parents and

Research recommendation Published October 2019

What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the post-surgical period of Crohn's disease?

Recommendation ID NG129/1 Question What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the

Research recommendation Published October 2019

What components of alcohol education delivery contribute to its effectiveness for children and young people aged 11 to 18 in full-time education, and those with special educational needs and disabilities (SEND) up to the age of 25?

Recommendation ID NG135/1 Question What components of alcohol education delivery contribute to its effectiveness for children and young

Research recommendation Published October 2019

The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices in primary care for people with signs or symptoms of atrial fibrillation, and an irregular pulse, increases the number of people with atrial fibrillation (including paroxysmal) detected, ompared with current practice (that is, a 12‑lead ECG done later). The committee considered the feasibility of collecting data to see if using the lead‑I ECG devices increased the detection of atrial fibrillation that would be missed if only 12‑lead ECGs done later were available. It noted that even if a lead‑I ECG is used and atrial fibrillation is detected, a subsequent 12‑lead ECG would still be done to check for structural cardiac abnormalities and inform further management decisions. The committee concluded that practices using lead‑I ECG devices could determine the number of additional cases of atrial fibrillation detected by the devices. This can be done by identifying people with a confirmed positive lead‑I ECG for atrial fibrillation who subsequently had a 12‑lead ECG that was negative because the atrial fibrillation had stopped. The committee also considered that data collected on the time between the initial lead‑I ECG and the subsequent 12‑lead ECG would be useful.

Recommendation ID DG35/1 Question The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices

Research recommendation Published October 2019

Learning disabilities and behaviour that challenges

Everything NICE has said on services, prevention and interventions for people with learning disabilities whose behaviour challenges in an interactive flowchart

NICE Pathway Published May 2015 Last updated October 2019

Lung cancer

Everything NICE has said on diagnosing and treating lung cancer in an interactive flowchart

NICE Pathway Published March 2012 Last updated October 2019

Dyspepsia and gastro-oesophageal reflux disease

Everything NICE has said on investigating and managing dyspepsia and gastro-oesophageal reflux disease in an interactive flowchart

NICE Pathway Published September 2014 Last updated October 2019

Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

Clinical guideline Published September 2014 Last updated October 2019

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

Technology appraisal guidance Published October 2019

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Midcarpal hemiarthroplasty for wrist arthritis (IPG663)

Evidence-based recommendations on midcarpal hemiarthroplasty (using a metal implant to create an artificial wrist joint) for wrist arthritis in adults

Interventional procedures guidance Published October 2019

Chest pain

Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart

NICE Pathway Published November 2016 Last updated October 2019

Lower limb peripheral arterial disease

Everything NICE has said on diagnosing and managing lower limb peripheral arterial disease in an interactive flowchart

NICE Pathway Published August 2012 Last updated October 2019

Myocardial infarction: rehabilitation and preventing further cardiovascular disease

Everything NICE has said on cardiac rehabilitation and preventing cardiovascular disease after myocardial infarction in an interactive flowchart

NICE Pathway Published November 2013 Last updated October 2019

End of life care for adults: service delivery (NG142)

This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

NICE guideline Published October 2019

End of life care for people with life-limiting conditions

Everything NICE has said about the care of people with a progressive life-limiting condition who are at the end of their life in an interactive flowchart

NICE Pathway Published March 2017 Last updated October 2019

Rheumatoid arthritis

Everything NICE has said on managing rheumatoid arthritis in adults in an interactive flowchart

NICE Pathway Published April 2013 Last updated October 2019

Osteoarthritis

Everything NICE has said on the care and management of osteoarthritis in adults in an interactive flowchart

NICE Pathway Published February 2014 Last updated October 2019

Blood and immune system conditions

Everything NICE has said on blood and immune system conditions in an interactive flowchart

NICE Pathway Published November 2014 Last updated October 2019

Violence and aggression

Everything NICE has said on managing violence in mental health, health and community settings in an interactive flowchart

NICE Pathway Published March 2014 Last updated October 2019

Head injury

Everything NICE has said on triage, assessment, investigation and management of head injury in infants, children and adults in an interactive flowchart

NICE Pathway Published January 2014 Last updated October 2019

Diabetic foot problems: prevention and management (NG19)

This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

NICE guideline Published August 2015 Last updated October 2019

Foot care for people with diabetes

Everything NICE has said on preventing and managing foot problems in children, young people and adults with type 1 or 2 diabetes in an interactive flowchart

NICE Pathway Published May 2011 Last updated October 2019

Harmful sexual behaviour among children and young people

Everything NICE has said on harmful sexual behaviour among children and young people (under 18s or under 25s with special educational needs or a disability) in an interactive flowchart.

NICE Pathway Published September 2016 Last updated October 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)

Highly specialised technologies guidance Published October 2019

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Technology appraisal guidance Published October 2019

Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

NICE guideline Published January 2015 Last updated October 2019

EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing

Medical technologies guidance Published January 2013 Last updated October 2019

Eye conditions

Everything NICE has said on eye conditions in an interactive flowchart

NICE Pathway Published November 2013 Last updated October 2019

Parkinson's disease

Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

NICE Pathway Published March 2014 Last updated October 2019

Motor neurone disease

Everything NICE has said on assessing and managing motor neurone disease in adults in an interactive flowchart

NICE Pathway Published November 2013 Last updated October 2019

Cerebral palsy

Everything NICE has said on cerebral palsy in an interactive flowchart

NICE Pathway Published January 2017 Last updated October 2019

Musculoskeletal conditions

Everything NICE has said on musculoskeletal conditions in an interactive flowchart

NICE Pathway Published December 2013 Last updated October 2019

Medicines optimisation

Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

NICE Pathway Published March 2015 Last updated October 2019

Familial hypercholesterolaemia: identification and management (CG71)

This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

Clinical guideline Published August 2008 Last updated October 2019

Familial hypercholesterolaemia

Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart

NICE Pathway Published August 2013 Last updated October 2019

Epilepsy

Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart

NICE Pathway Published January 2012 Last updated October 2019

Idelalisib for treating refractory follicular lymphoma (TA604)

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults

Technology appraisal guidance Published October 2019

Epilepsies: diagnosis and management (CG137)

The guideline covers diagnosing, treating and managing epilepsy and seizures in children, young people and adults in primary and secondary care. It offers best practice advice on managing epilepsy to improve health outcomes so that people with epilepsy can fully participate in daily life.

Clinical guideline Published January 2012 Last updated October 2019

Ulcerative colitis

Everything NICE has said on managing ulcerative colitis in adults, children and young people in an interactive flowchart

NICE Pathway Published June 2013 Last updated September 2019

Coexisting severe mental illness and substance misuse: community health and social care services

Everything NICE has said on severe mental illness and substance misuse (dual diagnosis) for people over 14 in community services in an interactive flowchart

NICE Pathway Published November 2016 Last updated September 2019

Colorectal cancer

Everything NICE has said on diagnosing and managing colorectal cancer in an interactive flowchart

NICE Pathway Published November 2011 Last updated September 2019

Cellulitis and erysipelas: antimicrobial prescribing (NG141)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Prevention and control of healthcare-associated infections

Everything NICE has said on preventing and controlling healthcare-associated infections in an interactive flowchart

NICE Pathway Published March 2012 Last updated September 2019

Cellulitis and erysipelas – antimicrobial prescribing

Everything NICE has said on antimicrobial prescribing for cellulitis and erysipelas in an interactive flowchart

NICE Pathway Published September 2019